Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Core Insights - The company plans to utilize the proceeds from a recent purchase agreement to expedite the development of Teverelix, a next-generation GnRH Antagonist targeting Acute Urinary Retention (AURr) and high cardiovascular risk Prostate Cancer [1] - Teverelix represents a significant market opportunity, estimated at approximately $6 billion [1] Company Developments - Medicus Pharma Ltd. has entered into a purchase agreement with YA II PL, Ltd. to support its clinical development programs [1] - The focus of the company is on advancing novel and disruptive therapeutic assets within the biotech and life sciences sector [1]